共 50 条
The incidence and risk of cardiovascular events associated with pembrolizumab in patients with breast cancer
被引:0
|作者:
Chiang, Cho-Han
[1
]
Xu, Xiaocao
[2
]
Song, Junmin
[3
]
Xanthavanij, Nutchapon
[1
]
Chi, Kuan-Yu
[3
]
Chang, Yu-Cheng
[4
]
Chang, Yu
[5
]
Hsiao, Chieh-Lien
[6
]
Hsia, Yuan Ping
[7
]
Chiang, Cho-Hung
[8
]
Lin, Shuwen
[9
]
机构:
[1] Harvard Med Sch, Mt Auburn Hosp, Dept Med, Cambridge, MA USA
[2] Univ Vermont, Dept Med, Div Hematol & Oncol, Med Ctr, Burlington, VT USA
[3] Albert Einstein Coll Med, Jacobi Med Ctr, Dept Med, Bronx, NY USA
[4] Danbury Hosp, Dept Med, Danbury, CT USA
[5] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Sect Neurosurg,Dept Surg, Tainan, Taiwan
[6] Columbia Univ, Sch Int & Publ Affairs, New York, NY USA
[7] Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Family Med, 289 Jianguo Rd, New Taipei 231405, Taiwan
[8] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[9] Albert Einstein Coll Med, Dept Oncol, Montefiore Einstein Canc Ctr MECC, Montefiore Med Ctr, Bronx, NY USA
来源:
关键词:
Cardiovascular events;
Cardiotoxicity;
Pembrolizumab;
Immune checkpoint inhibitor;
Breast cancer;
IMMUNE CHECKPOINT INHIBITORS;
D O I:
10.1016/j.canlet.2024.217277
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
引用
收藏
页数:4
相关论文